Transcriptome profiling reveals novel gene expression signatures and regulating transcription factors of TGFβ-induced epithelial-to-mesenchymal transition

Liutao Du¹, Shota Yamamoto¹, Barry L. Burnette¹, Danshang Huang¹, Kun Gao², Neema Jamshidi¹ & Michael D. Kuo¹,³

¹Department of Radiology, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095
²Department of Neurology, UCLA, Los Angeles, California 90095
³Department of Bioengineering, University of California-Los Angeles, Los Angeles, California 90095

Keywords
Breast, epithelial to mesenchymal transition, genomics, transcription factor, non-small-cell lung cancer

Abstract
Dysregulated epithelial to mesenchymal transition (EMT) in cancer cells endows invasive and metastatic properties upon cancer cells that favor successful colonization of distal target organs and therefore play a critical role in transforming early-stage carcinomas into invasive malignancies. EMT has also been associated with tumor recurrence and drug resistance and cancer stem cell initiation. Therefore, better understanding of the mechanisms behind EMT could ultimately contribute to the development of novel prognostic approaches and individualized therapies that specifically target EMT processes. As an effort to characterize the central transcriptome changes during EMT, we have developed a Transforming growth factor (TGF)-beta-based in vitro EMT model and used it to profile EMT-related gene transcriptional changes in two different cell lines, a non-small cell lung cancer cell line H358, and a breast cell line MCF10a. After 7 days of TGF-beta/Oncostatin M (OSM) treatment, changes in cell morphology to a mesenchymal phenotype were observed as well as concordant EMT-associated changes in mRNA and protein expression. Further, increased motility was noted and flow cytometry confirmed enrichment in cancer stem cell-like populations. Microarray-based differential expression analysis identified an EMT-associated gene expression signature which was confirmed by RT-qPCR and which significantly overlapped with a previously published EMT core signature. Finally, two novel EMT-regulating transcription factors, IRF5 and LMCD1, were identified and independently validated.

Introduction
The connection between epithelial mesenchymal transition (EMT) and cancer progression has been implicated in several types of cancer, including breast, prostate, pancreatic, and liver cancers [1–3]. Indeed, mounting evidence suggests that co-opting of EMT, an evolutionarily conserved process required for tissue morphogenesis during embryonic development, plays a critical role in tumor invasion, acquisition of cancer stem cell-like properties, and the development of metastasis and drug resistance [4]. While loss of E-cadherin expression represents a primal event in EMT, we increasingly appreciate that EMT is a complex process that is orchestrated by activation and repression of a growing and still incomplete list of genes, proteins, and transcriptional factors including ZEB1, SNAIL, TWIST, CDH2, and VIM among others [5–7]. Although several different EMT-related gene expression signatures (GES) have been reported to date attempting to capture key EMT-associated genes and regulators of EMT, they have been limited in part by variations observed between cell lines, limited concordance between different EMT induction models, and lack of functional validation [8–12]. Therefore, additional studies are still needed to identify both a robust, common set of EMT-associated genes and regulators in order to help improve our understanding.
of EMT, which could serve to drive future prognostic approaches and individualized therapies.

Here, we have developed a non-cell autonomous TGF-beta-based EMT induction model to profile and characterize the transcriptomic changes involved in the EMT process. After validation of our EMT induction model, we performed gene expression microarray analysis and identified a common set of EMT-related genes in two different cell lines which shows strong concordance with a previously reported EMT-GES. Finally, we report on two new EMT-regulating transcription factors (TFs) that have potential direct regulation of this unique process.

Materials and Methods

Cell culture and EMT induction

H358, MCF10a, and A549 cells used in this study were purchased from the American Type Culture Collection (ATCC) and grown as per ATCC protocols and cultured in an incubator at 37°C in the presence 5% CO2. For the EMT induction, untreated cells (preEMT) were treated with a combination of TGF-beta (10 ng/mL) and OSM (50 ng/mL) for 7 days (postEMT) and then subsequently analyzed for EMT induction. Cell medium was changed every 3 days and fresh TGF-beta and OSM were added with each medium change. TGF-beta and OSM were purchased from Cell Signaling Technology (Danvers, MA).

Microarray and IPA pathway analysis

All RNA samples for expression analysis were isolated using RNAeasy kit (Qiagen, Valencia, CA) and inspected for quality using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA) and gel electrophoresis in the University of California Los Angeles (UCLA) Clinical Microarray Core (UCMC). All the RNAs were confirmed to be high quality with RIN scores over 8. Gene expression profiling was performed using Agilent 8 × 60 k arrays (Agilent, Santa Clara, CA). The microarray data was processed with the edgeR package to analyze differential expression of genes [13]. Ingenuity pathway analysis (IPA) software (Qiagen, Redwood City, CA) was used for analysis of the signaling and metabolic pathways, molecular networks, and biological processes most significantly perturbed in the gene expression datasets [14]. IPA was also used to predict TFs, which could be responsible for gene expression changes and whether those TFs are activated or inhibited in EMT.

RT-qPCR and EMT-gene-qPCR array

Total RNA was extracted using RNAeasy kit (Qiagen, Valencia, CA). Reverse-transcription reactions were catalyzed by Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA). Subsequently, qPCR was performed using SensiFAST SYBR Lo-ROX Kit (Bioland Scientific, Paramount, CA) on an ABI Fast 7500 Real-Time PCR System (Life Technologies, Grand Island, NY). All the qPCR primers were designed and validated by standard curve approaches. Relative quantification values were calculated using the ddCt method after confirmation of equivalent amplification efficiencies between target genes and the reference gene. The EMT-gene qPCR array was purchased from Invitrogen (Life Technologies, Grand Island, NY). For all qPCR, two-step PCR cycling condition was used: 95°C for 2 min followed by 40 cycles of 95°C for 5 sec, 60°C for 20 sec. Primer sequences are available upon request.

siRNA knockdown and western blots

Cells were treated with siRNA against each individual gene at concentrations described per Lipofectamine® RNAiMAX protocol (Invitrogen, Carlsbad, CA). The sequences of the two IRF5 siRNAs used were previously published (Catalog #16708; Ambion, Austin, TX) and were purchased from Invitrogen (Life Technologies, Grand Island, NY) [15]. The predesigned triple siRNAs to LMCD1 were ordered from Integrated DNA Technologies Inc (Coralville, Iowa) and #1 and #2 were validated and used in experiments. For western blotting, cells were collected and whole cell lysate was prepared with RIPA buffer and used for target protein analysis. All antibodies were purchased from Cell Signaling (Danvers, MA) and were used for overnight incubation at 4°C according to manufacturers’ instructions.

Flow cytometry analysis

Cells were suspended in phosphate-buffered saline (PBS) with 20% fetal bovine serum (FBS) and incubated with relevant antibodies for 1 h on ice. Cells were then washed and resuspended with PBS + FBS for flow cytometry analysis (FACS) analysis on FACScanX (BD Biosciences, San Jose, CA) at the UCLA Flow Cytometry Core Laboratory. Antibodies against CD44 (PE-conjugated) and CD24 (APC-conjugated) were purchased from BD Biosciences (San Jose, CA); antibody against CD133 (PE-conjugated) was purchased from Miltenyi Biotec, (Cologne, Germany); antibody against E-cadherin (APC-conjugated) was purchased from Biolegend (San Diego, CA).

Cell invasion assay

Cell invasion was measured by CytoSelect™ 24-Well Cell Migration and Invasion Assay (Cell Biolabs, San Diego, CA).
CA) according to the manufacturer’s instructions. Briefly, the basement membrane layer of the cell culture inserts was rehydrated with serum-free media for 1 h. Media (10% FBS, 500 μL) was added to the lower well of the migration plate. Cells were prepared and suspended in serum-free media and were added to the inside of each insert and incubated for 48 h in an incubator. The media was aspirated from the inside of the insert, and nonmigratory cells were then removed. The insert was transferred to a clean well containing 400 μL of cell stain solution and incubated for 10 min and washed. Each insert was then transferred to an empty well and extraction solution was added at 200 μL per well, and then incubated for 10 min in an orbital shaker. From each sample, 100 μL was transferred to a 96-well microtiter plate and measured for OD 560 nm (BioTek, Winooski, VT).

**Results**

**Identification of an EMT-related gene expression signature by microarray analysis**

We optimized a TGF-beta-based EMT induction approach for use as an efficient and reproducible means of inducing EMT in different cell lines (H358 and MCF10a). A 7-day treatment of TGF-beta/OSM improved the efficiency of EMT induction, as compared to a single TGF-beta or OSM treatment, as demonstrated by protein expression changes of important EMT markers including E-cadherin, Vimentin, and Fibronectin (Fig. 1A; left panel: H358; right panel: MCF10a). TGF-beta/OSM was also more efficient for inducing EMT than other known EMT-inducing cytokines, such as HGF, FGF, and IGF (data not shown). In the H358 cells treated with TGF-beta/OSM, expression

---

**Figure 1.** An optimized TGF-beta/OSM approach to efficiently induce epithelial mesenchymal transition (EMT) in H358 and MCF10a cells. (A) Western Blot of EMT protein for H358 cells (left) and for MCF10a cells (right). After 7 days of exposure to TGF-beta/OSM, a clear loss of epithelial biomarker E-cadherin and increased expression of mesenchymal proteins vimentin and N-cadherin are shown; (B) RT-qPCR quantification of 12 important EMT genes in H358 cells treated with TGF-beta/OSM; (C) TGF-beta/OSM-induced CSC-like cells: CD44+/CD24− subpopulation in H358 cells and CD133+ subpopulation in MCF10a cells. (D) Mesenchymal morphological changes; (E) cell invasiveness. *P < 0.05.
of important EMT genes, such as CDH2, COL1A2, FN1, SNAI1, SNAI2, VIM, CDH1, and ERBB3, were all changed as expected after EMT induction (Fig. 1B). TGF-beta/OSM also significantly increased the CSC-like subpopulation cells in both cell lines (CD44+/CD24− or CD44+ in H358; CD133+ in MCF10a, Fig. 1C), induced mesenchymal morphological changes (Fig. 1D) and promoted cell invasiveness (Fig. 1E), which are consistent with previous reports.

To evaluate the transcriptomic changes during EMT in H358 and MCF10a cells, we used three independent sets of preEMT and postEMT RNA as biological triplicates for each cell line which were used for microarray-based gene expression profiling. We identified >2000 genes associated with EMT (fold change >2, and \( P < 0.05 \)). The top 50 significantly differentially expressed genes were listed in Table S1, all with fold change >16. A common GES of differentially expressed genes shared between the two cell lines consisting of 571 genes, with 269 genes upregulated and 302 genes downregulated (fold change >2, and \( P < 0.05 \)) was identified (Table S2). Among these genes, ~127 genes had fold change >4 in both cell lines. The top-10 upregulated common genes are SERPINB3, SERPINB4, SCG5, FAP, MMP9, GPR68, SERPINE1, CXCR7, ADAM19, and SLAMF8; the top-10 downregulated common genes are KRT15, PSCA, FGFBP1, FXYD3, MAL2, GPR110, C10orf116, S100P, SUSD2, and MYO5C. After comparing our 571-EMT-GES with a previously published 246-gene EMT-core-GES in breast cancer cells, we found 58 overlapping genes (=5 × 10^{-42}, hypergeometric distribution) (Table S3), suggesting that these genes are a part of a core set of EMT-genes that are neither tissue or cell type specific [8].

**Targeted validation of EMT transcriptomic profiles with RT-qPCR**

To confirm the accuracy of our EMT gene expression signature, we selected 25 genes from the top 50 upregulated and downregulated genes from our EMT GES and conducted RT-qPCR using newly prepared samples. The differential expression of all of these selected genes was successfully confirmed by RT-qPCR in this independent data set (Fig. 2). To further validate our microarray data results, we evaluated the mRNA levels of 65 genes that were previously reported to be related to EMT using a

---

**Figure 2.** RT-qPCR confirmation of the differential expression of selected top genes in H358 and MCF10a cells. Cells were induced with TGF-beta/OSM for 7 days and RNAs were prepared. The top genes differentially expressed were selected in each cell line and validated by RT-qPCR to confirm their expression differences (GADPH was used as reference control). (A) Expression confirmation of selected genes in H358 cells; (B) Expression confirmation of selected genes in MCF10a cells. All tested genes were significantly differentially expressed after epithelial mesenchymal transition-induction (\( P < 0.05 \)).
commercial RT-qPCR array and compared with our microarray data results. The expression changes for 62 out of 65 genes were validated (Table S4). The three genes that were not confirmed by the RT-qPCR EMT array had relatively low expression changes close to the cut-off ratio which was set at a fold change of 2. Together, these results confirm the reproducibility of our EMT-GES in independent samples.

**EMT-related TFs and signaling networks identified in the EMT-GES**

From our 571-EMT-GES, we found 34 TFs significantly differentially expressed during EMT induction (Table 1). The important known EMT-activating TFs, such as ZEB1, ZEB2, SNAI1, SNAI2, RUNX2, and ETS1, were all found upregulated, while known negative TF regulators of EMT, such as SMAD3, MITF, and ETF, were all downregulated in postEMT cells in concordance with the literature [16, 17]. IPA also identified a number of TFs that did not show significant differential expression changes in postEMT cells but were predicted to be activated or inhibited based on the expression profiles of their target genes. For example, TWIST1, TWIST2, HDAC6, MUC1, ETS2, NFkB, Jun, SP1, and AP1 were previously reported as enhancers of EMT, and were found activated in postEMT cells. Other TFs, such as ER, SPDEF, and HMGA1, were previously reported as repressors of EMT, and were found repressed in this study [18–20]. Interestingly, SMAD7 was previously reported as an EMT repressor; we found that SMAD7 gene expression was consistently elevated after EMT induction and positively correlated with postEMT [21]. IPA

| Gene   | Genbank ID | Log2FC in H358 | P-value in H358 | Log2FC in MCF10a | P-value in MCF10a | Averaged log2FC |
|--------|------------|----------------|-----------------|------------------|------------------|-----------------|
| ZEB1   | NM_001128128 | 3.42           | 7.67E-06        | 1.64             | 1.22E-02         | 2.53            |
| SNA1   | NM_005985   | 3.17           | 2.55E-05        | 4.1              | 7.50E-05         | 3.64            |
| SNA2   | NM_003068   | 2.6            | 7.61E-03        | 2.21             | 1.21E-02         | 2.41            |
| MAF    | NM_001031804 | 2.48          | 6.02E-04        | 1.63             | 6.16E-04         | 2.06            |
| ZEB2   | NM_014795   | 2.42           | 5.76E-04        | 1.3              | 7.03E-03         | 1.86            |
| ELK3   | NM_005230   | 1.92           | 1.25E-03        | 1.25             | 1.50E-03         | 1.59            |
| E2F7   | NM_203934   | 1.9            | 1.54E-02        | 1.04             | 6.46E-03         | 1.47            |
| SMAD7  | NM_005904   | 1.86           | 3.15E-03        | 2.47             | 1.02E-03         | 2.17            |
| ETS1   | NM_005238   | 1.85           | 1.49E-02        | 1.42             | 1.97E-03         | 1.63            |
| SNAI1  | NM_003069   | 1.77           | 1.29E-03        | 1.2              | 2.00E-02         | 1.49            |
| RAI14  | NM_015577   | 1.71           | 6.66E-03        | 1.74             | 1.93E-04         | 1.72            |
| TGFBI1 | NM_001042454 | 1.63        | 1.88E-03        | 2.12             | 2.03E-03         | 1.88            |
| LMCD1  | NM_014583   | 1.58           | 1.34E-02        | 4.5              | 8.46E-05         | 3.04            |
| SKIL   | NM_005414   | 1.56           | 1.20E-04        | 2.34             | 1.66E-03         | 1.95            |
| JARID2 | NM_004973   | 1.44           | 5.30E-03        | 1.34             | 1.32E-02         | 1.39            |
| RUNX2  | NM_004348   | 1.3            | 2.35E-02        | 3.57             | 7.23E-04         | 2.44            |
| JAZF1  | NM_175061   | 1.23           | 7.60E-03        | 1.24             | 1.57E-03         | 1.23            |
| ID2    | NM_002166   | 1.22           | 3.97E-02        | 1.5              | 4.24E-02         | 1.36            |
| RNF2   | NM_007212   | 1.11           | 5.58E-03        | 1.31             | 1.58E-02         | 1.21            |
| MTF    | NM_198159   | −1             | 4.39E-02        | −1.04            | 2.29E-02         | −1.02           |
| NFIB   | NM_005596   | −1             | 1.74E-02        | −2.88            | 2.18E-04         | −1.94           |
| ZNF488 | NM_153034   | −1.02          | 8.26E-03        | −1.19            | 3.94E-02         | −1.11           |
| EBF1X  | NM_001412   | −1.03          | 1.54E-02        | −1.05            | 3.77E-03         | −1.04           |
| PIR    | NM_003662   | −1.19          | 3.37E-02        | −1.39            | 3.72E-03         | −1.29           |
| EEFA12 | NM_001958   | −1.39          | 1.06E-02        | −1.03            | 2.99E-02         | −1.21           |
| TBL1X  | NM_005647   | −1.4           | 2.93E-03        | −1.25            | 7.93E-03         | −1.32           |
| ELL3   | NM_025165   | −1.42          | 1.94E-02        | −2.41            | 8.62E-05         | −1.92           |
| IKZF2  | NM_001079526 | −1.86        | 1.28E-03        | −1.48            | 8.96E-03         | −1.67           |
| TOB1   | NM_005749   | −1.88          | 1.76E-03        | −1.72            | 6.52E-03         | −1.8            |
| LSR    | NM_205834   | −1.93          | 1.94E-04        | −1.76            | 7.17E-03         | −1.85           |
| SMAD3  | NM_005902   | −1.94          | 1.06E-03        | −1.27            | 3.96E-03         | −1.61           |
| IRF5   | NM_001098627 | −2.37        | 7.92E-04        | −1.33            | 9.89E-04         | −1.85           |
| E2F2   | NM_004091   | −2.71          | 1.80E-02        | −2.62            | 9.89E-05         | −2.66           |
| OVOL2  | NM_021220   | −3.53          | 2.66E-05        | −1.27            | 8.67E-03         | −2.4            |
| EHF    | NM_012153   | −4.26          | 2.49E-06        | −1.85            | 8.14E-03         | −3.05           |
analysis also revealed that more than 10 networks (Nt) were activated during EMT; the top five common networks were shown in Fig. S1.

**Novel EMT-regulating TFs identified and validated by functional studies**

As shown in Table 1, certain TFs were found to be differentially expressed after EMT induction, however, their roles in EMT have not been previously reported. We focused on two TFs that may be involved in EMT regulation: IRF5 and LMCD1. IRF5's expression was significantly inhibited after EMT, whereas LMCD1's was significantly enhanced (Table 1). We first confirmed that IRF5 gene expression levels started to gradually decrease after EMT was induced by TGF-beta/OSM treatment, and then began to revert upon removal of the TGF-beta/OSM stimulus. Conversely, LMCD1 gene expression levels increased after EMT was induced, and then decreased after the EMT process was reversed (Figs. 3A and B). To study their potential roles in EMT regulation, we used gene-specific siRNAs to knockdown each of these individual TFs in H358 cells, and then exposed the siRNA-treated cells to TGF-beta/OSM to examine if the TGF-beta-mediated EMT was subsequently hindered or enhanced. To validate the siRNA knockdown, two different siRNAs were optimized and knockdown efficiency for each siRNA confirmed by RT-qPCR (Fig. 3C). We found that inhibition of IRF5-enhanced TGF-beta-mediated EMT progression, while conversely, knockdown of LMCD1 repressed TGF-beta-mediated EMT induction, as evidenced by the expression pattern of EMT protein biomarkers (Fig. 4A). FACS analysis of cell surface E-cadherin also indicated that knockdown of LMCD1 significantly reduced the E-cadherin-low-expressing cell subpopulation (from 9.8% to 4.2% (siR#1) or to 6% (siR#2), P < 0.05), while knockdown of IRF5 increased the E-cadherin-low-expressing cell subpopulation (from 9.8% to 13.9% (siR#1), or to 12.3% (siR#2), P < 0.05) (Fig. 4B). Knockdown of LMCD1 also significantly reduced cell invasiveness of TGF-beta/OSM-treated cells (P < 0.05) (Fig. 4C), but no significant effect was seen on the CD24+ or CD44+ cell subpopulations (Fig. 4D), as compared to the scrambled control-siRNA-treated cells. Conversely,

---

**Figure 3.** Time course of gene expression patterns of IRF5 and LMCD1 after 7 days of mesenchymal transition (EMT) induction with TGF-beta/OSM followed by removal of TGF-beta/OSM for 14 days and validation of siRNA-mediated knockdown efficiency of IRF5 and LMCD1 in H358 and MCF10a cells. (A) The relative expression levels of IRF5 and LMCD1 were measured by RT-qPCR in H358 and (B) MCF10a cells over a 21 days EMT induction-reversion time course in which the preEMT cells were first induced to undergo EMT via TGF-beta/OSM-based induction followed by removal of TGF-beta/OSM at day 7 (*P < 0.05; **P < 0.001, as compared to preEMT cells). (C) Confirmation of knockdown efficiency of selected siRNAs on LMCD1 and IRF5 gene expression in H358 cells; two siRNAs were optimized and used to knockdown their relative genes at 4 nmoL (**P < 0.001, as compared to scramble-siR control).
knockdown of IRF5 significantly promoted cell invasiveness of TGF-beta/OSM-treated cells (Fig. 4C), and dramatically increased the CD24+ subpopulation (from 0.4% to 35%, P < 0.001) and also increased the CD44+ subpopulation (from 6.2% to 14.9%, P < 0.05) (Fig. 4D), indicating its role in negative regulation of both CD24- and CD44- expressing cell populations during EMT. Further, cells treated with siR-IRF5 also showed a more EMT mesenchymal pattern compared with control cells after EMT induction, while cells treated with siR-LMCD1 had slightly reduced, but recognizable EMT morphologic features (Fig. S2, in both H358 and MCF10a).

To investigate whether these effects observed in H358 cells were cell type-dependent or not, we additionally conducted siRNA knockdown in breast MCF10a cells and a second lung cancer line, A549, that were both induced to undergo EMT by the same TGF-beta/OSM approach. Again, similar effects were observed in both cell lines. We also observed similar findings between MCF10a and H358 cells after knockdown of these two TFs; knockdown of IRF5 enhanced the EMT processes, while knockdown of LMCD1 inhibited EMT. These are indicated by the changes of critical EMT protein expression patterns (Fig. 5A), the E-cadherin-low-expressing cell subpopulation
Novel EMT-gene signature and regulating TFs
L. Du et al.

Discussion

EMT is believed to play a critical role in the cellular transformation to an invasive and ultimately metastatic cancer phenotype. However, a detailed understanding of the genes involved and their regulation is incompletely understood. Herein, we present an efficient model of EMT induction with TGF-beta/OSM in MCF10a and H358 cell lines. We show that this model faithfully recapitulates characteristics associated with EMT including appropriate changes in mRNA and protein expression of key EMT-associated markers as confirmed by both PCR and western analysis, changes in cell morphology, changes in distribution of CSC-cell populations, and alterations in cell motility. Using this model, we then characterized gene expression patterns involved with EMT transduction in both a cancerous and noncancerous cell line from two different tissue sites and define a shared EMT-associated GES from which we then independently validated the top differentially expressed genes by RT-qPCR. The strong overlap between the 58 genes identified from our EMT GES with a published core EMT GES suggest that these 58 genes may be part of a larger core set of EMT-genes that are neither tissue or cell type specific [8]. Further studies will be required to confirm this, but these results are nonetheless intriguing.
Interestingly, we found more than 10 networks activated during EMT. Nt 1 was centered on TGF-beta and involves nuclear proteins such as nup210, lipolysis-stimulated lipoprotein receptor (LSR), V-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MAF) and FILIP1L (Fig. S1). These proteins have been related to EMT regulation and cellular differentiation [22–25]. Nt2 was centered on NFkB and involved genes such as NFkB early-response gene IER3, secreted signaling molecules bone morphogenetic protein (BMP), and TF ETS homologous factor (EHT) that belongs to an ETS TF subfamily characterized by epithelial-specific expression and which may be involved in epithelial differentiation and carcinogenesis [26–29]. Nt3 was closely related to cancer and cellular movement being involved with the WNT pathway and ‘cadherin switch’ (repression of E-cadherin and expression of N-cadherin). Nt4 is related to cellular assembly and organization with vimentin and cytokeratin, and Nt5 involved signaling of cellular movement, cell-to-cell signaling, and interaction pathways regulated by SNAI1, SNAI2 and ZEB1, TGF-beta, WNT and BMP signaling pathways, which are believed to regulate embryonic stem cell progression. These data further substantiate the potential role these genes may have in EMT and CSC regulation [30].

Most interestingly, we identified two new TFs, IRF5 and LMCD1 that may play an important role in EMT induction. Our data suggest that LMCD1 acts as an enhancer of TGF-beta-dependent EMT processes, while IRF5 functions as a negative regulator of EMT. LMCD1 is a member of the LIM protein family containing two C-terminal LIM domains, a central PET domain, and an N-terminal cysteine-rich region [31]. LMCD1 was previously described as a transcriptional co-repressor of GATA6, whereas its role in cytoskeletal compartments remains to be elucidated [32]. LMCD1 E135K somatic mutation was associated with cell migration and tumor metastasis in hepatocellular carcinoma (HCC); its up-regulation was related to cancer and cellular movement being involved with the WNT pathway and ‘cadherin switch’ (repression of E-cadherin and expression of N-cadherin). Nt4 is related to cellular assembly and organization with vimentin and cytokeratin, and Nt5 involved signaling of cellular movement, cell-to-cell signaling, and interaction pathways regulated by SNAI1, SNAI2 and ZEB1, TGF-beta, WNT and BMP signaling pathways, which are believed to regulate embryonic stem cell progression. These data further substantiate the potential role these genes may have in EMT and CSC regulation [30].

Conversely, IRF5 has been reported as a tumor repressor in breast cancer and negatively regulates CD24 expression, but similarly, no association with date has been shown between IRF5 and EMT to the best of our knowledge [15, 34]. We also observed that IRF5 knockdown in preEMT H358 cells increased CD24+ cell subpopulation (from 0.6% to 4.1%, Fig. 4D, upper panel). Interestingly, we found that the IRF5-mediated CD24 repression is particularly significant and important for cells under exposure of EMT-inducing cytokines such as TGF-beta. Knockdown of IRF5 led to a much more dramatic increase in CD24+ expression in the cells exposed to TGF-beta/OSM, as compared to untreated cells. Knockdown of IRF5 also significantly increased CD44+ expression in postEMT cells, suggesting its critical repressive role in CD44 and CD24 regulation during EMT.

Finally, but no less interestingly, we found that SMAD7, a reported EMT repressor that antagonizes TGF-beta signaling [35], was actually significantly upregulated in postEMT cells in our EMT model in both H358 and MCF10a cell lines (Table 1). Heikkinen et al. reported that hypoxic conditions could convert SMAD7 function from an inhibitor into a promoter of cell invasion in cancer, which was supported by evidence that increased SMAD7 expression in human cancer correlated with hypoxic gene expression. Further studies are needed to better understand how SMAD7 functions during EMT and metastasis [36].

Taken together, our data help shed new light into the transcriptional landscape of EMT and its regulation. Future studies will need to continue to address how these numerous EMT-related networks, and regulating genes such as TFs, are dynamically orchestrated during EMT. This could eventually result in development of new prognostic tools and biomarkers, and provide promising targets for the development of novel EMT-based treatments for cancers.

Acknowledgment
None.

Conflict of Interest
None declared.

References
1. Hugo, H., M. L. Ackland, T. Blick, M. G. Lawrence, J. A. Clements, E. D. Williams, et al. 2007. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J. Cell. Physiol. 213:374–383.
2. Lee, T. K., R. T. Poon, A. P. Yuen, M. T. Ling, W. K. Kwok, X. H. Wang, et al. 2006. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 12:5369–5376.
3. Xiao, D., and J. He. 2010. Epithelial mesenchymal transition and lung cancer. J. Thorac. Dis. 2:154–159.
4. Baum, B., J. Settleman, and M. P. Quinlan. 2008. Transitions between epithelial and mesenchymal states in development and disease. Semin. Cell Dev. Biol. 19:294–308.
5. Yang, M.-H., M.-Z. Wu, S.-H. Chiou, P.-M. Chen, S.-Y. Chang, C.-J. Liu, et al. 2008. Direct regulation of
TWIST by HIF-1α promotes metastasis. Nat. Cell Biol. 10:295–305.
6. Liu, Y., J. Yin, W. Abou-Kheir, P. Hynes, O. Casey, L. Fang, et al. 2013. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 32:296–306.
7. Weinberg, R. A. 2008. Twisted epithelial–mesenchymal transition blocks senescence. Nat. Cell Biol. 10:1021–1023.
8. Taube, J. H., J. I. Herschkowitz, K. Komurov, A. Y. Zhou, S. Gupta, J. Yang, et al. 2010. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. 107:15449–15454.
9. Singh, A., P. Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, et al. 2009. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15:489–500.
10. Chung, C. H., J. S. Parker, K. Ely, J. Carter, Y. Yi, B. A. Murphy, et al. 2006. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 66:8210–8218.
11. Byers, L. A., L. Diao, J. Wang, P. Saintigny, L. Girard, M. Peyton, et al. 2013. An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19:279–290.
12. Anastassiou, D., V. Rumjantseva, W. Cheng, J. Huang, P. D. Canoll, D. J. Yamashiro, et al. 2011. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer 11:529.
13. Robinson, M. D., D. J. McCarthy, and G. K. Smyth. 2010. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140.
14. Jiménez-Marín, Á., M. Collado-Romero, M. Ramirez-Boo, C. Arce, and J. J. Garrido. 2009. Biological pathway analysis by arrayunlock and ingenuity pathway analysis. BMC Proc. 3:S6.
15. Bi, X., M. Hameed, N. Mirani, E. M. Pimenta, J. Anari, and B. J. Barnes. 2011. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 13:R111.
16. Anseieau, S., A. Morel, G. Hinkal, J. Bastid, and A. Puissieux. 2010. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 29:3173–3184.
17. Welbhe, M., S. M. Soudja, A. Mas, L. Chasson, R. Guinamard, de Tenbossche C. P., et al. 2012. Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in mice. PLoS One. 7:e49419.
29. Duangkumpha, K., A. Techasen, W. Loilome, N. Namwat, R. Thanan, N. Khuntikeo, et al. 2014. BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma. Tumour Biol. 35:9667–9676.
30. Kurek, D., A. Neagu, M. Tastemel, N. Tüysüz, J. Lehmann, van de Werken H. J., et al. 2015. Endogenous WNT signals mediate BMP-induced and spontaneous differentiation of epiblast stem cells and human embryonic stem cells. Stem Cell Reports 4:114–128.
31. Bespalova, I. N., and M. Burmeister. 2000. Identification of a novel LIM domain gene, LMCD1, and chromosomal localization in human and mouse. Genomics 63:69–74.
32. Rath, N., Z. Wang, M. M. Lu, and E. E. Morrisey. 2005. LMCD1/Dyxin is a novel transcriptional cofactor that restricts GATA6 function by inhibiting DNA binding. Mol. Cell. Biol. 25:8864–8873.
33. Chang, C., S. Lin, W. Su, C. Ho, and Y. Jou. 2012. Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. Oncogene 31:2640–2652.
34. Yanai, H., H.-M. Chen, T. Inuzuka, S. Kondo, T. W. Mak, A. Takaoka, et al. 2007. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl Acad. Sci. 104:3402–3407.
35. Zhang, S., T. Fei, L. Zhang, R. Zhang, F. Chen, Y. Ning, et al. 2007. Smad7 antagonizes transforming growth factor β signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol. Cell. Biol. 27:4488–4499.
36. Heikkinen, P. T., M. Nummela, T. Jokilehto, R. Grenman, V.-M. Kähäri, and P. M. Jaakkola. 2010. Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion. Cancer Res. 70:5984–5993.

Supporting Information

Additional supporting information may be found in the online version of this article:

Figure S1. Top common EMT-related networks identified by IPA in H358 and MCF10a cells. Network (Nt1): TGF-β-centered pathways. Nt2 involved in NFkB activation. Nt3 closely related to cancer and cellular movement, being involved with WNT pathway and ‘cadherin switch’; Nt 4 related to cellular assembly and organization with vimentin and cytokeratin; Nt5 involved signaling of cellular movement, cell-to-cell signaling and interaction.

Figure S2. Effects of knockdown of IRF5 or LMCD1 on cell morphology in H358 and MCF10 cells that were induced to EMT. Cells were treated with each siRNA for 48 h at 6 nmol/L followed by induction of EMT using TGF-beta/OSM for 3 days. (A) H358 cells; (B) MCF10a cells. Cells treated with siR-IRF5 and siR-LMCD1 showed more EMT morphologic pattern compared with control cells.

Table S1. Top 50 genes differentially expressed in H358 and MCF10a cells.

Table S2. Common differentially expressed EMT genes shared between H358 and MCF10a.

Table S3. 58 core EMT-related genes shared by our GES and Gupta’s GES.

Table S4. RT-qPCR validation of 65 known EMT-associated genes.